Novavax Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.63next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Adjusted Total Revenue Annually140MTarget: 230000000 to 270000000
Non-GAAP Combined R&D and SG&A Expenses Annually
Cash and Accounts Receivable Quarterly818MTarget: Sufficient to fund operations into 2028
Watch Items
- Sanofi Phase 3 COVID-Influenza Combination Vaccine Trial InitiationTrigger: Initiation of Phase 3 trialAction: Triggers a $125 million milestone payment from Sanofi
- Nuvaxovid Manufacturing Technology Transfer to SanofiTrigger: Successful completion of technology transferAction: Triggers a $75 million milestone payment from Sanofi
- Matrix-M Adjuvant Licensing and MTA ExpansionsTrigger: Signing of new material transfer agreements or commercial licensesAction: Evaluate upfront cash, development milestones, and royalty structures to accelerate path to profitability
Research as of 19 Jun 2026